"The authors believe that these coronavirus specific viral entry inhibitors may have utility in a drug combination therapy with other anti - SARS-CoV-2 drugs that have different mechanisms of action, such as remdesivir (the viral RNA dependent RNA polymerase inhibitor), or lysomotropic autophagy inhibitors."